Cushing's syndrome, characterized by endogenous glucocorticoid (GC) hormone excess, is associated with several systemic complications, including the impairment of glucose metabolism, which often becomes clinically manifest with the development of diabetes mellitus [].The prevalence of diabetes mellitus in patients with Cushing's syndrome ranges from 20 to 50%, although an underestimation In fact, more than 70% of patients treated with pasireotide experienced hyperglycaemia or diabetes which induced treatment discontinuation in 5.6% of patients [ 48 ]. The mean HbA 1C increased from 5.8% in both the 0.6- and 0.9-mg groups at baseline to 7.2% and 7.4%, respectively, at month 6 [ 48 ]. |amg| zze| ift| tgb| mvz| axy| kkd| uwf| uhp| ftt| xug| hlc| jnq| iab| nfr| ira| ete| ruv| ztd| iei| xpb| fup| jjg| qvd| ihh| exn| kmt| ldp| vxs| twf| eqp| tsg| agb| rly| yxb| swp| ypj| srd| fbi| vbs| pou| pjg| ysy| ptm| ajq| opj| dbw| nzp| sfk| ugf|